# Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

> **NCT01781611** · NA · TERMINATED · sponsor: **Oklahoma Medical Research Foundation** · enrollment: 18 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** extended release dipyridamole 200mg/aspirin 25mg
- **DRUG:** 81mg aspirin

## Key facts

- **NCT ID:** NCT01781611
- **Lead sponsor:** Oklahoma Medical Research Foundation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2017-05
- **Final completion:** 2017-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01781611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01781611, "Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01781611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*